Astellas B.V. and Astellas Pharma Europe B.V., Astellas' subsidiaries in Netherlands, have made an intended decision to sell and transfer its manufacturing plant, located in Meppel, the Netherlands, to Delpharm Industrie SAS. The definitive agreement will be executed after completing works council consultation and local legal and regulatory requirements.

Astellas is committed to the process of optimizing resources to adapt and successfully perform in a rapidly changing business environment. This includes the areas of technology and manufacturing in which Astellas actively strengthens its capabilities and develops ties with partners to promote a stable supply of high-quality medicines. As part of these efforts, Astellas B.V. and Astellas Pharma Europe B.V. have made the intended decision to sell and transfer the Business to Delpharm.

Upon the transfer of the Business to Delpharm, the plan is that Delpharm will continue to manufacture the products that are currently manufactured at the plant in Meppel and will deliver these products to Astellas group to ensure the stable supply of products for patients. This collaboration between Delpharm and Astellas will allow Astellas to utilize a high-quality and efficient outsourced manufacturing system in Meppel. As part of the sale and transfer of the Business, the employees will also transfer to Delpharm.

On the Meppel site with an area of more than 46,000 m2 is located a factory with an area of 21,000 m2. The site specializes in the production of pharmaceutical forms tablets, capsules, and granule medicines. Annual production is approx.1.3 billion tablets, approx. 50 million packs, and approx. 80 tones granules. As of May 2023, the site employs 332 people.

The Completion of transfer to Delpharm is planned for the fourth quarter of 2023